An Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Three Dosing Regimens of Oral AT2220 in Patients With Pompe Disease
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 3
- 主要终点
- Proportion Of Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)
研究概览
简要总结
The main purpose of this study was to determine the safety and tolerability of 3 different doses of duvoglustat (AT2220) in participants affected by Pompe disease. The study also evaluated the effects of duvoglustat on functional parameters in Pompe disease.
详细描述
This was a Phase 2, open-label study in participants with Pompe disease, a lysosomal storage disorder. Duvoglustat is designed to act as a pharmacological chaperone of alpha-glucosidase, in order to restore enzyme activity. This study consisted of a 28-day screening period, an 11-week treatment period, and a 1-week follow-up period. Three dosing regimens of oral duvoglustat were to be evaluated (Cohort 1: 2.5 g daily for 3 days, followed by no study drug for 4 days; Cohort 2: 5 g daily for 3 days, followed by no study drug for 4 days; Cohort 3: 5 g daily for 7 days, followed by no study drug for 7 days).
Participants meeting all eligibility criteria underwent physical examination, electrocardiogram, spirometry, muscular strength test, functional muscle test, 6-minute walk test (when appropriate), laboratory tests, magnetic resonance imaging, and muscle (needle) biopsy. Quality of life was assessed via the 36-Item Short Form Health Survey questionnaire. Functional ability and level of handicap was assessed by Rotterdam handicap scale.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18 to 74 years of age inclusive
- •Diagnosis of Pompe disease based on clinical assessment, enzyme assay, and/or genotyping. Confirmatory genotyping will be performed on all participants who are screened for the study
- •Naïve to enzyme replacement therapy (ERT) or has not received ERT in the 3 months prior to screening
- •Willing not to initiate ERT or other prohibited treatment during study participation
- •Functional grade for arms and/or legs ≥2 OR sitting forced vital capacity ≥30% and <80% of predicted value, reproducible between screening and baseline (±15%)
- •Participants of reproductive potential agree to use reliable methods of contraception during the study
- •Participant or legal representative is willing and able to provide written informed consent
排除标准
- •Any intercurrent condition that may preclude accurate interpretation of study data
- •Obstructive pulmonary disease
- •Invasive ventilatory support
- •Use of noninvasive ventilatory support >8 hours/day while awake
- •History of QTc prolongation >450 milliseconds (msec) for males and >470 msec for females
- •History of allergy or sensitivity to the study drug, including any prior serious adverse reaction to iminosugars (such as miglustat or miglitol)
- •Pregnancy or breast-feeding
- •Current or recent drug or alcohol abuse
- •Treatment with another investigational drug within 30 days of study start
- •Use of prohibited medications ≤3 months prior to screening
- •Otherwise unsuitable for the study in the opinion of the Investigator
研究组 & 干预措施
Cohort 2
Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks.
干预措施: Duvoglustat (Drug)
Cohort 3
Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks.
干预措施: Duvoglustat (Drug)
Cohort 1
Regimen 1: Low-dose duvoglustat (2.5 grams [g]) once a day (QD) for 3 days, followed by no drug for 4 days, for 11 weeks.
干预措施: Duvoglustat (Drug)
结局指标
主要结局
Proportion Of Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)
时间窗: Baseline, Week 11
The number of participants experiencing severe TEAEs is presented for participants who received duvoglustat treatment in this open-label study. The duration of duvoglustat exposure for Cohort 1 ranged from 2 to 24 days, and their exposure ranged from a total of 7,500 to 32,500 milligrams of duvoglustat. An adverse event (AE) refers to any unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during the period of observation in the clinical study. The following guideline was used to grade the intensity of an AE: mild, the AE is easily tolerated and does not interfere with daily activity; moderate, the AE interferes with the daily activity but the participant is still able to function; severe, the AE is incapacitating and requires medical intervention. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
次要结局
- Change In 6-minute Walk Test (6MWT) From Baseline To End Of Study(Baseline, Week 11)